Cargando…

Clinical study of poorly differentiated head and neck squamous cell carcinoma: a prospective cohort study in China

BACKGROUND: Although poorly differentiated is rare in head and neck squamous cell carcinoma (HNSCC), its prognosis are worse with high rate of local recurrence and distant metastasis (DS). Therefore, this study hopes to carry out prospective clinical research on different treatment options for poorl...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Shuo, Guo, Wei, Yin, Gaofei, Li, Nuan, Liu, Hongfei, Huang, Junwei, Yang, Zheng, Xu, Hongbo, Chen, Xiaohong, Zhang, Yang, Huang, Zhigang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279816/
https://www.ncbi.nlm.nih.gov/pubmed/35845503
http://dx.doi.org/10.21037/atm-22-2630
_version_ 1784746486120054784
author Ding, Shuo
Guo, Wei
Yin, Gaofei
Li, Nuan
Liu, Hongfei
Huang, Junwei
Yang, Zheng
Xu, Hongbo
Chen, Xiaohong
Zhang, Yang
Huang, Zhigang
author_facet Ding, Shuo
Guo, Wei
Yin, Gaofei
Li, Nuan
Liu, Hongfei
Huang, Junwei
Yang, Zheng
Xu, Hongbo
Chen, Xiaohong
Zhang, Yang
Huang, Zhigang
author_sort Ding, Shuo
collection PubMed
description BACKGROUND: Although poorly differentiated is rare in head and neck squamous cell carcinoma (HNSCC), its prognosis are worse with high rate of local recurrence and distant metastasis (DS). Therefore, this study hopes to carry out prospective clinical research on different treatment options for poorly differentiated patients and explore the treatment scheme more suitable for these patients. METHODS: This study is a prospective cohort study. We selected patients with poorly differentiated carcinoma in larynx or hypopharynx (stage I–IV, T1–4a, N0–2, M0). The intervention treatment methods for stage I–II patients are as follows: surgery, induction chemotherapy (IC) + surgery, surgery + adjuvant therapy; The intervention treatment methods for stage III–IV patients are as follows: surgery, IC + surgery + adjuvant therapy, surgery + adjuvant therapy. The patients were followed up for at least 1 year, and the disease progression and survival were counted. RESULTS: From September 2016 to October 2020, 62 patients were included (29 patients in stage I/II and 33 patients in stage III/IV). We found that there was no significant difference in survival between treatment groups in stage I/II patients [overall survival (OS): P=0.447; progression free survival (PFS): P=0.504], but the surgery + adjuvant treatment group had a significant advantage in 3-year OS (100%). In stage III/IV patients, there were significant differences in DS, OS and PFS between different treatment groups (DS: P=0.013; OS: P=0.021; PFS: P=0.020). Among them, the survival rate of IC + surgery + adjuvant treatment group was the best, with 3-year OS of 78%. CONCLUSIONS: Our study found that postoperative radiotherapy may improve the OS rate of patients with early (stage I/II) poorly differentiated HNSCC; For advanced patients (stage III/IV), surgery combined with IC and postoperative adjuvant radiotherapy may better control DS and improve the survival rate. However, our study draws the above conclusions based on small sample data, and we will continue to summarize and expand the sample size for verification.
format Online
Article
Text
id pubmed-9279816
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-92798162022-07-15 Clinical study of poorly differentiated head and neck squamous cell carcinoma: a prospective cohort study in China Ding, Shuo Guo, Wei Yin, Gaofei Li, Nuan Liu, Hongfei Huang, Junwei Yang, Zheng Xu, Hongbo Chen, Xiaohong Zhang, Yang Huang, Zhigang Ann Transl Med Original Article BACKGROUND: Although poorly differentiated is rare in head and neck squamous cell carcinoma (HNSCC), its prognosis are worse with high rate of local recurrence and distant metastasis (DS). Therefore, this study hopes to carry out prospective clinical research on different treatment options for poorly differentiated patients and explore the treatment scheme more suitable for these patients. METHODS: This study is a prospective cohort study. We selected patients with poorly differentiated carcinoma in larynx or hypopharynx (stage I–IV, T1–4a, N0–2, M0). The intervention treatment methods for stage I–II patients are as follows: surgery, induction chemotherapy (IC) + surgery, surgery + adjuvant therapy; The intervention treatment methods for stage III–IV patients are as follows: surgery, IC + surgery + adjuvant therapy, surgery + adjuvant therapy. The patients were followed up for at least 1 year, and the disease progression and survival were counted. RESULTS: From September 2016 to October 2020, 62 patients were included (29 patients in stage I/II and 33 patients in stage III/IV). We found that there was no significant difference in survival between treatment groups in stage I/II patients [overall survival (OS): P=0.447; progression free survival (PFS): P=0.504], but the surgery + adjuvant treatment group had a significant advantage in 3-year OS (100%). In stage III/IV patients, there were significant differences in DS, OS and PFS between different treatment groups (DS: P=0.013; OS: P=0.021; PFS: P=0.020). Among them, the survival rate of IC + surgery + adjuvant treatment group was the best, with 3-year OS of 78%. CONCLUSIONS: Our study found that postoperative radiotherapy may improve the OS rate of patients with early (stage I/II) poorly differentiated HNSCC; For advanced patients (stage III/IV), surgery combined with IC and postoperative adjuvant radiotherapy may better control DS and improve the survival rate. However, our study draws the above conclusions based on small sample data, and we will continue to summarize and expand the sample size for verification. AME Publishing Company 2022-06 /pmc/articles/PMC9279816/ /pubmed/35845503 http://dx.doi.org/10.21037/atm-22-2630 Text en 2022 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Ding, Shuo
Guo, Wei
Yin, Gaofei
Li, Nuan
Liu, Hongfei
Huang, Junwei
Yang, Zheng
Xu, Hongbo
Chen, Xiaohong
Zhang, Yang
Huang, Zhigang
Clinical study of poorly differentiated head and neck squamous cell carcinoma: a prospective cohort study in China
title Clinical study of poorly differentiated head and neck squamous cell carcinoma: a prospective cohort study in China
title_full Clinical study of poorly differentiated head and neck squamous cell carcinoma: a prospective cohort study in China
title_fullStr Clinical study of poorly differentiated head and neck squamous cell carcinoma: a prospective cohort study in China
title_full_unstemmed Clinical study of poorly differentiated head and neck squamous cell carcinoma: a prospective cohort study in China
title_short Clinical study of poorly differentiated head and neck squamous cell carcinoma: a prospective cohort study in China
title_sort clinical study of poorly differentiated head and neck squamous cell carcinoma: a prospective cohort study in china
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279816/
https://www.ncbi.nlm.nih.gov/pubmed/35845503
http://dx.doi.org/10.21037/atm-22-2630
work_keys_str_mv AT dingshuo clinicalstudyofpoorlydifferentiatedheadandnecksquamouscellcarcinomaaprospectivecohortstudyinchina
AT guowei clinicalstudyofpoorlydifferentiatedheadandnecksquamouscellcarcinomaaprospectivecohortstudyinchina
AT yingaofei clinicalstudyofpoorlydifferentiatedheadandnecksquamouscellcarcinomaaprospectivecohortstudyinchina
AT linuan clinicalstudyofpoorlydifferentiatedheadandnecksquamouscellcarcinomaaprospectivecohortstudyinchina
AT liuhongfei clinicalstudyofpoorlydifferentiatedheadandnecksquamouscellcarcinomaaprospectivecohortstudyinchina
AT huangjunwei clinicalstudyofpoorlydifferentiatedheadandnecksquamouscellcarcinomaaprospectivecohortstudyinchina
AT yangzheng clinicalstudyofpoorlydifferentiatedheadandnecksquamouscellcarcinomaaprospectivecohortstudyinchina
AT xuhongbo clinicalstudyofpoorlydifferentiatedheadandnecksquamouscellcarcinomaaprospectivecohortstudyinchina
AT chenxiaohong clinicalstudyofpoorlydifferentiatedheadandnecksquamouscellcarcinomaaprospectivecohortstudyinchina
AT zhangyang clinicalstudyofpoorlydifferentiatedheadandnecksquamouscellcarcinomaaprospectivecohortstudyinchina
AT huangzhigang clinicalstudyofpoorlydifferentiatedheadandnecksquamouscellcarcinomaaprospectivecohortstudyinchina